openPR Logo
Press release

Vienna: The Human Genome on 6 x 4 cm - Symposium on Molecular Diagnostics

06-29-2006 03:56 PM CET | Health & Medicine

Press release from: PR&D - Public Relations for Research & Development

/ PR Agency: PR&D - Public Relations for Research and Development
The importance of molecular diagnostics for cancer treatment is set to increase significantly in coming years, according to a symposium held yesterday in Vienna. The reason for organising the symposium was the acquisition of a cutting-edge microarray analyser as part of the EU OVCAD (Ovarian Cancer Diagnosis) project. The device provides what is currently the most sensitive technology for analysing the activity of all human genes and therefore enables the type and progress of cancers to be determined with previously unattainable levels of accuracy.

Tumour cells differ from the body's normal cells in that they exhibit altered genetic activity. Identifying this activity provides a basis for making an early and accurate clinical diagnosis, but the key is knowing what to look for – not such an easy task given that the human body contains approx. 30,000 genes. Nonetheless, the EU OVCAD project, being coordinated at the Medical University of Vienna, has made a major breakthrough in the molecular diagnosis of ovarian cancer by acquiring the world’s most sensitive device for comparing the genetic activity of all human genes. The potential offered by this technology was discussed at the symposium.

30,000 Genes on 4 x 6 cm
One benefit of the device – the 1700 Chemiluminescence Microarray Analyzer from US company Applied Biosystems – that stood out in particular was its ability to measure profiles of the gene activity of all 30,000 human genes with unrivalled sensitivity. In actual fact, the device is capable of measuring the activity of almost 8,000 more genes than similar devices – and all within a unique dynamic measuring range. This state-of-the-art technology provides a clear clinical benefit because any gene whose activity differs between cancerous and healthy cells can be identified without the need for prior knowledge of which genes are to be analysed.

However, Professor Robert Zeillinger, Head of the "Molecular Oncology" Working Group at the Medical University of Vienna and Coordinator of OVCAD, believes the system holds even greater potential: "We intend to analyse genetic activity in tumour cells in patients with ovarian cancer as part of the EU OVCAD project. We are interested in particular in differences between patients who are responding to chemotherapy and those for whom this standard treatment is not working. Analysing these differences will enable predictions to be made about the potential success of chemotherapy at the time of diagnosis rather than a number of months later when the tumour has grown significantly, as was previously the case."

But this in no way exhausts the potential offered by microarray analysis. For instance, Eva Obermayer, a member of Zeillinger's working group, is evaluating the possibility of using this technology to find evidence of individual scattered cancer cells which can contribute to the recurrence of the cancer even after successful treatment of the primary tumour. Combining use of the technology with a highly efficient method for amplifying nucleotide sequences enables these individual cancer cells to be detected in blood samples, assuming the relevant altered gene activity is known. Information that can also be obtained with the 1700 Chemiluminescence Microarray Analyzer.

3D Diagnosis
Zeillinger is convinced that such possibilities herald a new era for cancer diagnosis where, thanks to the detail of information it provides, diagnosis forms an integral part of treatment. Whereas diagnosis previously took a more one-dimensional approach, focusing on detecting the existence of an already-established tumour, the molecular approaches add a further two dimensions to diagnosis by providing details on tumour biology and the success of treatment. This will enable earlier and more specific treatment. At the end of the symposium, participants agreed that findings from the OVCAD project will undoubtedly also contribute to improved diagnosis of other forms of cancer.

Background: OVCAD - OVarian CAncer Diagnosis - is a Specific Targeted Research Project (STREP) into cancer diagnostics under the umbrella of the EU's Sixth Framework Programme. The project aims to identify molecular markers that enable conclusions to be made about the future success of ovarian cancer treatment at the time of diagnosis. OVCAD comprises 11 academic and 4 industrial partner groups from France, Belgium, the Netherlands, Israel, Germany and Austria. The project will run for three years and is receiving Euro 4.26 million in funding from the EU. It is being coordinated by the Department of Obstetrics and Gynaecology at the Medical University of Vienna.

Scientific Contact:
Prof. Robert Zeillinger
Medical University of Vienna
Department of Obstetrics and Gynaecology
Währinger Gürtel 18-20, 5Q
A-1190 Vienna
T +43 / 664 / 4240373

Copy Editing & Distribution:
PR&D - Public Relations for Research & Development
Campus Vienna Biocenter 2
A-1030 Vienna
T +43 / 1 / 505 70 44

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Vienna: The Human Genome on 6 x 4 cm - Symposium on Molecular Diagnostics here

News-ID: 9798 • Views: 1400

More Releases from PR&D - Public Relations for Research & Development

Vienna, 2 September 2008. The International Balzan Foundation will announce the winners of this year’s prestigious Balzan prizes on 8 September 2008 in Milan. The foundation will be awarding the prizes in honour of exceptional research in Preventive Medicine, the Science of Climate Change, the Visual Arts Since 1700 and Moral Philosophy. The prizes, which are each worth one million Swiss Francs, are to be presented on 21 November in
"Wanted - spaceship engine noise" Intelligent sound database developed
St. Poelten, AUSTRIA 26 May 2008 – From 30 May 2008, media producers will be able to access an efficient and easy-to-use new technology that will help them track down the sound effects they need. After two and a half years of development work, the AllThatSounds (ATS) intelligent database for sounds and noises is going online at . The database has been designed and developed by a research
A recently approved project of the sixth EU Framework Programme – MimoVax – is focussing on a new target for an Alzheimer's vaccine. The project, coordinated by the Austrian company Affiris GmbH, centres on the use of immune reactions to combat previously overlooked forms of the beta-amyloid that cause Alzheimer's disease. It is being run by seven partner organisations from three countries and has received an exceptionally positive response from
Standardised employment contracts based on the \"equal work, equal pay\" principle boost motivation. There is a clear increase in performance levels and market efficiency compared to working conditions based on individually negotiated contracts. This important finding was uncovered by scientists from the University of Innsbruck, Austria, as they analysed results from an economic experiment. The project, supported by the Austrian Science Fund (FWF), has attracted great interest in Austria, as

All 5 Releases

More Releases for Vienna

Blue bleu blau blu 2017 Vienna
BIENNALE AUSTRIA association presents on occasion of the exhibition "blue bleu blau blu 2017 Vienna“ positions of artists from Australia, Denmark, Egypt, Germany, Finland, Israel, Italy, Kenya, Netherlands, Russia, Switzerland, Serbia and Austria on the subject of BLUE from 16 – 22 October 2017 at AUSSTELLUNGSRAUM, Gumpendorfer Strasse 23, 1060 Vienna, Austria. “Leonardo da Vinci describes the nature and effect of the color BLUE as immaterial, BLUE is not a color
InterNetX at Domain pulse 2011 in Vienna
(REGENSBURG – VIENNA, February 17, 2011) – This year, the German-speaking branch meeting Domain pulse is taking place on February 17 and 18, 2011 in the Austrian city of Vienna, with the participation of InterNetX. It is the third time that the Austrian registry is hosting the event in the capital city. The historical Palais Ferstel is the backdrop for this eighth Domain pulse event and provides the perfect
Vienna Tour Company, Vienna City Tours Announces New Website
Vienna City Tours, a company that offers guided tours in Vienna, Austria, announces their new website. The company offers many different types of Vienna tours that can be personalized to fit any tourist. VIENNA, AUSTRIA – Vienna City Tours, a company that specializes in guided tours in Vienna, recently announced their new website design. The website allows customers to easily find what types of tours are available and is full of information
VIENNA DESIGN WEEK - Vienna – A City Full of Design
The aim of VIENNA DESIGN WEEK is to show and enable people to experience the many-faceted creative work in the fields of product, furniture and industrial design, but also positions of experimental design. After a successful first festival last year, the work of numerous designers from Austria and abroad will also be presented this October with a growing programme of events. International Design in Vienna In cooperation
2006 Mozart Year in Vienna/Austria
From January 27 to 29 there will be a great party in Vienna celebrating Mozart`s 250th birthday. It will be an open party for everyone. Mozart`s birthday will be celebrated all over the city with music, films, and several other, sometimes surprising themes. There are five different tours: Mozart Friends and Enemies Mozart Viennese and Cosmopolitan Mozart Art and Love Mozart Life and Death Mozart Yesterday and Today Each of these special Mozart Tours contains four
European Venture Market Vienna
European Venture Market Vienna November 8th – 9th 2005 Nationalbibliothek – Wien The European Venture Market is a platform to facilitate the meeting of entrepreneurs and investors. It is a platform for any kind of financing with focus to equity. Giving the wide variety of investors joining the platform the Market is also suitable for any sectors. The European Venture Market is informal, discrete, personal and professional. Meet professionals with a high